Abstract: Disclosed are methods and compositions for treating cognitive decline in subjects in need. More specifically, disclosed are methods of administrating exogenous adropin to subjects suffering from, or at risk of, cognitive decline. Also disclosed are subjects who would benefit from such treatment and pharmaceutical acceptable compositions comprising adropin, adropin34-76, and derivatives or variations thereof.
Type:
Grant
Filed:
June 4, 2019
Date of Patent:
April 30, 2024
Assignees:
Saint Louis University, U.S. Department of Veternas Affairs
Inventors:
Andrew Alistair Butler, Susan Farr, Clemence Girardet